The IBMCB was established in March 2012 as a result of the merger of the Institute of Biological Research and Biotechnology (IBRB) and the Institute of Organic and Pharmaceutical Chemistry (IOPC) of the NHRF. The objective of IBMCB is to act as a focal point of Excellence, through an interdisciplinary approach in the area of Chemical Biology with the aim of providing solutions for state-of-the-art issues in the areas of health, drug research, and biotechnology.
In Greece, no other Institute currently employs an analogous integrated multidisciplinary approach to disease prevention and treatment, combining cutting edge biological research (biological target identification, biological evaluation of bioactive agents) with synthetic and medicinal chemistry and molecular analysis (rational design and synthesis of bioactive compounds – potential drugs to combat major diseases and targeted delivery formulations).
The IBMCB aspires to play a key role, nationally and internationally, in research for drug discovery and biological target identification, as well as in research on high added-value fine chemicals, biotech products and processes, relying on the exploitation of the synergy between Chemistry and Biology, the expertise of its research staff and its significant state-of-the-art infrastructure.
